```markdown
---
title: "Precision Neuroscience Closes $120M Series D to Accelerate Cortical Array Commercialization"
date: 2026-06-24
category: Funding
excerpt: "Precision Neuroscience raises $120M Series D to expand its minimally invasive cortical BCI toward broader clinical indications and commercial scale."
sponsored: false
---
Precision Neuroscience announced today the close of a $120 million Series D funding round, bringing its total capital raised to over $290 million since the company's founding in 2021. The round was led by General Catalyst, with participation from existing investors including Microsoft's M12 venture fund and Coatue Management. The fresh capital will be directed toward expanded clinical trials, regulatory submissions, and manufacturing scale-up for the company's Layer 7 Cortical Interface, a thin-film electrode array designed to sit on the surface of the brain without penetrating cortical tissue.
Where the Capital Goes
Precision Neuroscience's leadership stated that a significant portion of the Series D will fund a pivotal trial targeting patients with ALS and severe motor impairments, with an IDE submission to the FDA anticipated before the end of Q3 2026. The company also plans to open two additional surgical sites in Europe, supplementing existing clinical relationships in the United States. Beyond the core motor restoration indication, the company disclosed early-stage feasibility work in epilepsy monitoring and speech decoding, areas where the non-penetrating form factor may offer a meaningful safety profile advantage over traditional depth electrodes. Manufacturing investment will focus on bringing electrode fabrication partially in-house, reducing per-unit costs and tightening quality control ahead of any commercial pathway.
Competitive Context
The announcement arrives at a particularly active moment for the cortical BCI space. Synchron continues to advance its endovascular Stentrode platform through ongoing U.S. trials, while Neuralink recently reported updated data from its PRIME study cohort at the BCI Society annual meeting earlier this month. Precision's differentiation argument has consistently centered on procedural reversibility and scalability, positioning the Layer 7 array as a product neurosurgeons can implant in under an hour without violating the blood-brain barrier. Investors appear to be pricing that narrative favorably, particularly given increasing FDA attention to long-term device safety and the agency's draft guidance on implantable neural interface biocompatibility published in March 2026.
Looking Ahead
With regulatory timelines tightening and competitive pressure mounting, the next eighteen months will be a critical test of whether Precision Neuroscience can translate its strong early clinical data into a durable commercial position. The company's CEO indicated that a pre-market approval application for the primary motor restoration indication remains the 2027 horizon goal. Industry observers will be watching enrollment velocity in the pivotal trial and whether the expanded European sites can accelerate the patient data needed to support that submission.